A Possible simplification for the estimation of area under the curve (AUC0-12) of enteric-coated mycophenolate sodium in renal transplant patients receiving tacrolimus

Therapeutic Drug Monitoring

Volumn 33, Issue 2, 2011, Pages 165-170

  Fleming, Denise H ^a   Mathew, Binu S ^a   Prasanna, Samuel ^a   Annapandian, Vellaichamy M ^b   John, George T ^b  

^a CHRISTIAN MEDICAL COLLEGE   (India)

^b Christian Medical College ^*  (India)

Author keywords

AUC; mycophenolate sodium; renal transplantation; simplified strategy; therapeutic drug monitoring

Indexed keywords

MYCOPHENOLIC ACID; PREDNISOLONE; TACROLIMUS;

ACCURACY; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; ENTERIC COATED TABLET; HUMAN; KIDNEY TRANSPLANTATION; LINEAR REGRESSION ANALYSIS; MAXIMUM PLASMA CONCENTRATION; MULTIPLE REGRESSION; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION; VALIDATION STUDY;

AREA UNDER CURVE; DELAYED-ACTION PREPARATIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; PREDNISOLONE; REPRODUCIBILITY OF RESULTS; TABLETS, ENTERIC-COATED; TACROLIMUS; TIME FACTORS;

EID: 79953196091     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31820c16f8     Document Type: Article

References (27)

1. Roth D, Colona J, Burke GW, et al. Primary immunosuppression with tacrolimus and mycophenolate mofetil for renal allograft recipients. Transplantation. 1998;65:248-252. (Pubitemid 28099219)
2. Shaw LM, Nicholls A, Hale M, et al. Therapeutic monitoring of mycophenolic acid-a consensus panel report. Clin Biochem. 1998;31: 317-322. (Pubitemid 28385228)
3. Budde K, Glander P, Kramer B, et al. Conversion from mycophenolate mofetil to enteric coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic and pharmacodynamic outcomes. Transplantation. 2007;83:417-424. (Pubitemid 46667845)
4. Behrend M, Braun F. Enteric-coated mycophenolate sodium: tolerability profile compared with mycophenolate mofetil. Drugs. 2005;65:1037-1050. (Pubitemid 40840002)
5. Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant. 2004;4:237-243. (Pubitemid 38248527)
6. De Winter BC, Van Gelder T, Glander P, et al. Population pharmacokinetics of mycophenolic acid. A comparison between enteric coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients. Clin Pharmacokinet. 2008;47:827-838.
7. Budde K, Bauer S, Hambach P, et al. Pharmacokinetic and pharmacodynamic comparison of enteric coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. Am J Transplant. 2007;7:888-898. (Pubitemid 46481185)
8. Sommerer C, Muller-Krebs S, Schaier M, et al. Pharmacokinetic and pharmacodynamic analysis of enteric coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. Br J Clin Pharmacol. 2010;69:346-357.
9. Shaw LM, Holt DW, Oellerich M, et al. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit. 2001;23:305-315. (Pubitemid 32708913)
10. Van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation. 1999;68: 261-266. (Pubitemid 29360288)
11. Mourad M, Malaise J, Chaib Eddour D, et al. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem. 2001;47:88-94. (Pubitemid 32064280)
12. Van Gelder T, Le Meur Y, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit. 2006;28: 145-154. (Pubitemid 44314941)
13. Kuypers DRJ, De Jonge H, Naesens M, et al. Current target ranges of mycophenolic acid exposure and drug related adverse events: a 5 year open label, prospective clinical follow up study in renal allograft recipients. Clin Ther. 2008;30:673-683. (Pubitemid 351689045)
14. Shaw LM, Kaplan B, De Nofrio D, et al. Pharmacokinetics and concentration control investigations of mycophenolic acid in adults after transplantation. Ther Drug Monit. 2000;22:14-19. (Pubitemid 30083089)
15. Filler G. Abbreviated mycophenolic acid AUC from CO, C1, C2, and C4 is preferable in children after renal transplantation on mycophenolate mofetil and tacrolimus therapy. Transplant Int. 2004;17:120-125. (Pubitemid 38660687)
16. Zicheng Y, Weixia Z, Hao C, et al. Limited sampling strategy for the estimation of mycophenolic acid area under the plasma concentration time curve in adult patients undergoing liver transplant. Ther Drug Monit. 2007;29:207-214. (Pubitemid 46716188)
17. Weber LT, Hoecker B, Armstrong VW, et al. Validation of an abbreviated pharmacokinetic profile for the estimation of mycophenolic acid exposure in pediatric renal transplant recipients. Ther Drug Monit. 2006;28: 623-631. (Pubitemid 44564060)
18. Ng J, Rogosheske J, Barker J, et al. A limited sampling model for estimation of total and unbound mycophenolic acid (MPA) area under the curve (AUC) in hematopoietic cell transplantation (HCT). Ther Drug Monit. 2006;28:394-401. (Pubitemid 44314928)
19. Mathew BS, Fleming DH, Annapandian VM, et al. A reliable limited sampling strategy for the estimation of mycophenolic acid area under the concentration time curve in adult renal transplant patients in the stable post transplant period. Ther Drug Monit. 2010;32:136-140.
20. Pawinski T, Hale M, Korecka M, et al. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem. 2002; 48:1497-1504. (Pubitemid 34925784)
21. Kuypers DRJ, Claes K, Evenepoel P, et al. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients. J Clin Pharmacol. 2003;43:866-880. (Pubitemid 36886107)
22. Catteneo D, Perico N, Gaspari F, et al. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int. 2002;62:1060-1067. (Pubitemid 35316738)
23. Van Hest R, Van Gelder T, Bouw R, et al. Time-dependent clearance of mycophenolic acid in renal transplant recipients. Br J Clin Pharmacol. 2007;63:741-752. (Pubitemid 46753575)
24. Weber LT, Lamersdorf T, Shipkova M, et al. Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients. German Study Group on mycophenolate mofetil therapy in pediatric renal transplant recipients. Ther Drug Monit. 1999;21:498-506. (Pubitemid 29468315)
25. Fleming DH, Mathew BS, John GT, et al. A six-hour extrapolated sampling strategy for monitoring mycophenolic acid in renal transplant patients in the Indian subcontinent. J Postgrad Med. 2006;52:248-252. (Pubitemid 44862761)
26. Wong KM, Shek CC, Chau KF, et al. Abbreviated tacrolimus area under the curve monitoring for renal transplant recipients. Am J Kidney Dis. 2000;35:660-666.
27. Suarez-Kurtz G, Bozza FA, Vicente FL, et al. Limited sampling strategy models for itraconzole and hydroxyl-itraconazole based on data from a bioequivalence study. Antimicrob Agents Chemother. 1999;43: 134-140. (Pubitemid 29069212)